Merck KGaA’s dual immuno-oncology weapon misfires
Bintrafusp alfa’s most important study, head to head against Keytruda in front-line lung cancer, is scrapped.
SITC 2020 – embargo snafu triggers the first movers
The SITC breaks its own embargo, and the ensuing chaos sees Replimune, Iovance and Incyte move.
Clinical data focus for the smallest players
Our final look at upcoming catalysts sees data expected from Replimune, TCR2 Therapeutics, Anavex and more.
Scholar thinks Glaxo made a wise move to back Merck
Scholar Rock selects a lead molecule inhibiting TGF-β, an increasingly important oncology mechanism that Glaxosmithkline recently paid €300m to enter.
